Enhertu approved in China for HER2-positive early Breast cancer with residual disease

Datroway approved in China for metastatic TNBC ineligible for PD-1/PD-L1 inhibitors

AbbVie’s Temab-A receives FDA Breakthrough Therapy Designations for CRC and NSCLC

[²¹²Pb]PSV359 receives FDA Fast Track Designation for FAP-positive solitary fibrous tumors

Crescent Biopharma receives FDA IND clearance for CR-002 in Solid tumors

AstraZeneca and Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway plus Ivonescimab across multiple...